Natural and synthetic analogues of actinomycin D as Grb2-SH2 domain blockers. 2000

H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
Korea Research Institute of Bioscience and Biotechnology, Yusung, Taejon, South Korea.

Natural analogues (D, C2, and VII) of actinomycin inhibit Grb2 SH2 domain binding with phosphopeptide-derived from Shc in vitro and in intracellular system. To study structure-activity relationships, 13 actinomycin analogues were synthesized and we found that the inhibition activity depended on the substituents of cyclic peptide groups in actinomycin and two analogues with Tyr residue are the most potent inhibitors with IC50 value of 0.5 and 0.8 microM, respectively.

UI MeSH Term Description Entries
D011233 Precipitin Tests Serologic tests in which a positive reaction manifested by visible CHEMICAL PRECIPITATION occurs when a soluble ANTIGEN reacts with its precipitins, i.e., ANTIBODIES that can form a precipitate. Precipitin Test,Test, Precipitin,Tests, Precipitin
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D011993 Recombinant Fusion Proteins Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes. Fusion Proteins, Recombinant,Recombinant Chimeric Protein,Recombinant Fusion Protein,Recombinant Hybrid Protein,Chimeric Proteins, Recombinant,Hybrid Proteins, Recombinant,Recombinant Chimeric Proteins,Recombinant Hybrid Proteins,Chimeric Protein, Recombinant,Fusion Protein, Recombinant,Hybrid Protein, Recombinant,Protein, Recombinant Chimeric,Protein, Recombinant Fusion,Protein, Recombinant Hybrid,Proteins, Recombinant Chimeric,Proteins, Recombinant Fusion,Proteins, Recombinant Hybrid
D002461 Cell Line, Transformed Eukaryotic cell line obtained in a quiescent or stationary phase which undergoes conversion to a state of unregulated growth in culture, resembling an in vitro tumor. It occurs spontaneously or through interaction with viruses, oncogenes, radiation, or drugs/chemicals. Transformed Cell Line,Cell Lines, Transformed,Transformed Cell Lines
D003609 Dactinomycin A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015) Actinomycin,Actinomycin D,Meractinomycin,Cosmegen,Cosmegen Lyovac,Lyovac-Cosmegen,Lyovac Cosmegen,Lyovac, Cosmegen,LyovacCosmegen
D006131 Growth Inhibitors Endogenous or exogenous substances which inhibit the normal growth of human and animal cells or micro-organisms, as distinguished from those affecting plant growth ( Cell Growth Inhibitor,Cell Growth Inhibitors,Growth Inhibitor,Growth Inhibitor, Cell,Growth Inhibitors, Cell,Inhibitor, Cell Growth,Inhibitor, Growth,Inhibitors, Cell Growth,Inhibitors, Growth
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071425 Src Homology 2 Domain-Containing, Transforming Protein 1 An SHC-signaling adaptor protein that transduces PHOSPHOTYROSINE-dependent signals downstream of RECEPTOR PROTEIN-TYROSINE KINASES and non-receptor tyrosine kinases. It is required for TGF-BETA-induced CELL MIGRATION; NEOLPASM INVASION; and METASTASIS of BREAST NEOPLASMS; its SH2 DOMAIN is essential for tumor survival. It also functions in signaling downstream of ANGIOPOIETIN RECEPTOR TIE-2, regulating the migration of ENDOTHELIAL CELLS; and PHYSIOLOGIC NEOVASCULARIZATION. SHC (Src Homology 2 Domain-Containing) Transforming Protein 1,SHC-Transforming Protein 1,SHC1 (Src Homology 2 Domain-Containing) Protein,SHC1 Protein,ShcA Protein,Src Homology 2 Domain-Containing-Transforming Protein C1,SHC Transforming Protein 1,Src Homology 2 Domain Containing Transforming Protein C1,Src Homology 2 Domain Containing, Transforming Protein 1
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
January 2003, Biopolymers,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
January 1999, Bioorganic & medicinal chemistry letters,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
June 2007, Archives of biochemistry and biophysics,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
July 2012, Chembiochem : a European journal of chemical biology,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
January 2023, Methods in molecular biology (Clifton, N.J.),
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
October 2019, Biomolecular NMR assignments,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
August 2010, Biochemical and biophysical research communications,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
July 2003, Bioorganic & medicinal chemistry letters,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
June 2001, Bioorganic & medicinal chemistry,
H K Kim, and J Y Nam, and M Y Han, and K H Son, and J D Choi, and B M Kwon, and H L Takusagawa, and Y Huang, and F Takusagawa
October 1998, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!